Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged Roivant
Does Arbutus’ patent suit against Moderna’s Covid vaccine have a testing problem?

I’ve blogged several times about the ongoing patent dispute between Arbutus and Moderna.  The case is nearing the end of expert discovery and is headed for trial towards the end of 2025.  A recent discovery dispute between the parties highlighted an important issue to watch as the case nears trial.  The dispute concerns Arbutus’ testing of Moderna’s vaccine—Moderna claims that the parameters used to setup the testing may have been faulty.  Does Arbutus have a testing problem, or Moderna grasping for straws in the face of troubling test results?

Read More
Markman AdvisorsModerna, Moderna Therapeutics, MRNA, Arbutus, Arbutus Biopharma, Genevant, Roivant, lipid nanoparticle, Daubert, summary judgment, molar ratio, Zachary Silbersher, SilbersherComment
Why did Acuitas bring a patent lawsuit against Arbutus?

The LNP patent battle lines are being drawn. In the past several weeks, Arbutus has sued Moderna, Alnylam has suedboth Moderna and Pfizer, and in the latest, Acuitas Therapeutics has sued Arbutus and Genevant. What can we expect from the Acuitas lawsuit?

Read More
Markman AdvisorsArbutus, Arbutus Biopharma, Genevant, Roivant, Moderna, Pfizer, BioNTech, LNP, lipid, lipid nanoparticle, cationic lipid, lawsuit, patent, license, IPR, royalty, Acuitas, Acuitas Therapeutics, Alnylam, Zachary Silbersher, Silbersher, ABUS, MRNA, PFE Comment